Managed care expects to broaden Crestor use

More good news for AstraZeneca's Crestor: Managed care pharmacy directors are saying they'll pay for the statin for healthy patients without high LDL cholesterol, but with elevated high sensitivity C-reactive protein, after the Jupiter trial found outcomes benefits from Crestor use in those patients. Release

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.